Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France

Similar documents
Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France

Optimal management of auto-immune

Autoimmune Hepatitis. Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern. November 14th, 2018

Autoimmune Hepatitis in Clinical Practice

Serologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I

Patterns of abnormal LFTs and their differential diagnosis

Chronic Hepatitis B Infection

Patterns of abnormal LFTs and their differential diagnosis

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP

Autoimmune Hepatitis. What Drug and for How Long? Hepatology Day May 30 th, 2015

Autoimmune Hepatitis: Defining the need for Liver Transplantation

Hépatite auto-immune. aigue sévère

Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood

Chronic Hepatitis. Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh

Novel Therapies in Autoimmune Hepatitis

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES

CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease

Module 1 Introduction of hepatitis

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

Hépatopathies auto-immunes

Hangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam

Clinical Case Maria Butí, MD, PhD

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Current Concepts in the Management and Treatment of PBC & PSC

PBC features and management in the era of UDCA and Budesonide

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes

Diseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob:

TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)

Pediatric Primary Sclerosing Cholangitis and Potential Therapies

Drug-induced liver injury

Approach to Abnormal Liver Tests

Trapianto di fegato e organi solidi. Pierluigi Toniutto Sezione di Epatologia e Trapianto Epatico Università di Udine

Liver transplantation and hepatitis C virus

Alcoholic Hepatitis: Management Options

Transplant Hepatology

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

8 Larissa International Congress of Internal Medicine

MANAGEMENT OF IMMUNOTHERAPY RELATED GI AND HEPATIC ADVERSE EVENTS

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

Approach to the Patient with Liver Disease

Hepatology For The Nonhepatologist

Hepatitis C Update on New Treatments

A Rational Evidence-based Approach to Abnormal Liver Tests

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries

Investigations before OLT, Immunosuppression and rejection, Follow up after OLT.

The future of liver transplantation for viral hepatitis

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland

budesonide, 3mg, gastro-resistant capsules (Budenofalk ) SMC No. (1043/15) Dr Falk Pharma UK Ltd

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

How to improve long term outcome after liver transplantation?

EVALUATION OF ABNORMAL LIVER TESTS

Hepatorenal Syndrome

Invasive. Sampling error. Interobserver variability. Nondynamic evaluation of

Current Concepts in Diagnosis and Management of Acute Liver Failure

Update in abdominal Surgery in cirrhotic patients

Hepatology for the Nonhepatologist

Comparing Efficacy Between Regimens in the Initial Treatment of Autoimmune Hepatitis

Viral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

The Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust

4/3/2014. Elizabeth Thompson, PharmD April Understand the importance of the liver and basic physiology.

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Hepatocellular Carcinoma: Diagnosis and Management

Trapianto di fegato e organi solidi. Pierluigi Toniutto Sezione di Epatologia e Trapianto Epatico Università di Udine

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

New York State HCV Provider Webinar Series. Overview of Fibrosis Staging, Child s Pugh, MELD Scores

LIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA

ACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society

Worldwide Causes of HCC

Key Aspects of Diagnosing Alcoholic Hepatitis. Mark Sonderup University of Cape Town & Groote Schuur Hospital

Domenico ALVARO, MD Sapienza, University of Rome, Italy. Congresso Nazionale della Società Italiana di GastroReumatologia, Roma, 25 Giugno 2015.

Healthy Liver Cirrhosis

Liver Function Testing. in primary care. Quiz Feedback

Treatment of chronic hepatitis delta Case report

DECISION. Minister of Ministry of Health. Decides:

Viral Hepatitis. Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP

The Efficacy of Corticosteroid Therapy in a Patient with Nonalcoholic Steatohepatitis Overlapping Autoimmune Hepatitis: A Case Report

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries

Recurrent HCV after a Pre-LTx Course of SOF/DAC:

Kalliopi Azariadi, Pinelopi Arvaniti, Nikolaos Gatselis, George N. Dalekos, Kalliopi Zachou

Key Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto

GI bleeding in chronic liver disease

Biliary tract diseases of the liver

World Health Organization. Western Pacific Region

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

Pediatric PSC A children s tale

Acute Liver Failure. Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018

Clinical Features and Long Term Outcome of 102 Treated Autoimmune Hepatitis Patients

Pretreatment Evaluation

Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017

Hepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona

Risk stratification in PBC

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Transcription:

Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France

41 year-old woman, coming to emergency department for fatigue and jaundice Medical history Delivery of a healthy boy 10 weeks before No medication or substance abuse No alcohol Physical examination 55 kg; 1.65 m Jaundice

Laboratory results 28/07/2013 AST (IU/L) (< 31) 1191 ALT (IU/L) (<34) 1444 ALK (IU/L) (<100) 108 GGT (IU/L) (<38) 167 Bilirubin (µmol/l) 73 INR 1.2 Platelet count 376

Ultrasound Normal liver aspect No hepatic vein thrombosis No ascites

Work-up for causes: HBs Ag undetectable Anti-HCV Ab undetectable Anti-HEV IgM undetectable Anti-HAV IgM undetectable Ceruloplasmin level normal Copper level normal IgG Auto-antibodies 36 g/l (<16g/L) waiting

Question What would you do at that stage?

Liver biopsy PT PT PT Courtesy Pr P Bedossa

Plasmocyte CLV CLV

Work-up for causes: Anti-HAV IgM undetectable HBs Ag undetectable Anti-HCV Ab undetectable Anti-HEV IgM undetectable Ceruloplasmin level normal Copper level normal IgG 36 g/l (<12 g/l) Auto-antibodies anti-sma 1/80

Question What treatment would you propose?

Prednisolone 30 mg/day Azathioprine 50 mg/day 28/07/2013 26/08/2016 AST (IU/L) (< 31) 1191 30 ALT (IU/L) (<34) 1444 29 ALK (IU/L) (<100) 108 80 GGT (IU/L) (<38) 167 50 Bilirubin (µmol/l) 73 17 INR 1.2 1.0 Platelet count 376 290

1 year later: Normal AST and ALT levels Normal IgG levels Azathioprine 100 mg/day Desires a new pregnancy

Question Is pregnancy contraindicated?

Question Regarding therapy, what would you suggest? 1. Interrupt Azathioprine no treatment 2. Interrupt Azathioprine give prednisolone 3. Interrupt Azathioprine give MMF 4. Maintain Azathioprine at the same dose

Question Regarding therapy, what would you suggest? 1. Interrupt Azathioprine no treatment 2. Interrupt Azathioprine give prednisolone 3. Interrupt Azathioprine give MMF 4. Maintain Azathioprine at the same dose

Question The patient wants to know the expected maternal and foetal outcome. What do you tell her?

Fetal outcome 81 pregnancies at King s college (1982-2009) Percentage 70 60 50 40 30 20 Cirrhosis at conception N=22 N=12 N=47 10 0 Fetal loss Preterm Term Schramm C, AJG 2006; Westbrook RH, J Autoimmun 2012; Heneghan MA, Gut 2001

Maternal outcome 81 pregnancies at King s college (1982-2009) No maternal complication N=50 Death or transplantation within 12 months N=6 N=25 No treatment for AIH Flare in AIH Schramm C, AJG 2006; Westbrook RH, J Autoimmun 2012; Heneghan MA, Gut 2001

Question Is breastfeeding possible in this patient with aziathioprine?

Breastfeeding in AIH Data derived from use for other conditions Considered safe for breastfeeding (small amounts of metabolite detected in breastmilk) Angelberger S, J Crohns Colitis 2011 Christensen LA, Aliment Pharmacol Ther 2008

Take home messages Controlled AIH is neither a contraindication to pregnancy nor to breastfeeding Maintenance of azathioprine +/- predniso(lo)ne Mild flares can occur in the 1st trimester and in particular after delivery and may require transient increase in immunosuppression MMF is contraindicated in pregnancy

Case 2

57 year-old woman, coming to emergency department for jaundice Medical history Lupus erythematosus No medication or substance abuse No alcohol Physical examination 61kg; 1.68 m Jaundice; no hepatic encephalopathy

Laboratory results 05/03/2009 AST (IU/L) (< 31) 2981 ALT (IU/L) (<34) 3685 ALK (IU/L) (<100) 339 GGT (IU/L) (<38) 565 Bilirubin (µmol/l) 292 INR 2.2 Platelet count 165

Ultrasound: irregular liver surface; No ascites No hepatitis A, B, C or E virus infection Anti-antinuclear Ab: 1/320 γ-globulin level: 9 g/l (normal < 12) Liver biopsy: Massive hepatocellular necrosis Mild inflammatory infiltrate No cirrhosis

Question What do you propose?

Prednisolone 30 mg/day Azathioprine 50 mg/day 05/03/2009 20/03/2009 AST (IU/L) (< 31) 2981 297 ALT (IU/L) (<34) 3685 509 ALK (IU/L) (<100) 339 347 GGT (IU/L) (<38) 565 402 Bilirubin (µmol/l) 292 614 INR 2.2 2.4 Platelet count 165 150

Prednisolone 30 mg/day Azathioprine 50 mg/day AST (IU/L) (< 31) ALT (IU/L) (<34) ALK (IU/L) (<100) GGT (IU/L) (<38) Bilirubin (µmol/l) INR Platelet count 05/03/2009 2981 3685 339 565 292 2.2 165 20/03/2009 297 509 347 Emergency liver 402 transplantation 614 2.4 150 Hepatic encephalopathy

Severe forms of AIH Can respond and be controlled In favor of steroids Risk of severe sepsis Against steroids

Severe forms of AIH 32 patients with AIH and INR 1.5 Corticosteroids (n=23) MELD: 28* No corticosteroids (n=9) MELD: 34* No LT N=13 LT N=10 LT N=9 6 death Yeoman, J Hepatol 2014

Yeoman, J Hepatol 2014 Yeoman, Hepatology 2011 Severe forms of AIH All patients should be considered for a trial of corticosteroids at the earliest Failure to improve serum bilirubin or MELD-Na within 7 days: strong negative prognostic value consider LT

The patient improved and was discharged from hospital 1 month later You see the patient 4 mo after transplantation Liver blood tests are normal

Question How do you manage immunosupressive therapy?

AIH following liver transplantation Recurrent AIH: 20 25% of cases Usually managed by or re-instituting corticosteroids Gautam M, Liver Transpl 2006 Carbone M, J Hepatol 2014

Case 3

61 year-old woman, referred by a gastroenterologist for abnormal liver blood tests Medical history Crohn s disease treated with Azathioprine (not tolerated), then Infliximab No medication or substance abuse No alcohol Physical examination Normal

25/08/2016 AST (IU/L) (< 31) 56 ALT (IU/L) (<34) 28 ALK (IU/L) (<100) 127 GGT (IU/L) (<38) 68 Bilirubin (µmol/l) 14 INR 1.63 Platelet count 125

No hepatitis A, B, C or E virus infection Anti-antinuclear Ab: 1/160 γ-globulin level 24,5 g/l (normal < 12) Transjugular liver biopsy: Hepatic venous pressure gradient: 22 mm Hg Advanced fibrosis Dense plasma cell-rich lymphoplasmocytic infiltrates

HA PV BD Courtesy Pr P Bedossa

Question What do you propose to this patient not tolerating azathioprine? - No treatment since ALT levels normal - Budesonide - Prednisolone - MMF - Tacrolimus

Should AIH be systematically treated? Mild disease - ALT <3x ULN - Mild histological activity - No advanced fibrosis Treatment can optional, taking into account: age co-morbidity patient preference Feld, Hepatology 2005